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Care for men with prostate cancer is a major global health care challenge, compounded by an aging population and increasing frequency of diagnosis. The priorities today are similar to those in the recent past: 
minimizing overtreatment of indolent disease and improving outcomes for pa-
tients with aggressive disease. Herein we focus on recent accomplishments and 
future challenges in the management of metastatic disease, which continues to be 
associated with a high rate of death despite multiple new-drug approvals in recent 
years. Metastatic prostate cancer can be broadly divided into two groups: disease 
that has not been treated with androgen deprivation and disease that is resistant 
to such therapy. Treating metastatic prostate cancer is becomingly increasingly 
complex. We review studies that are changing the standard of care, and we offer 
a conceptual perspective for addressing ongoing challenges and opportunities.
Me ta s tatic Dise a se No t Pr e v iously Tr e ated  
w i th A ndro gen Depr i vation
In 1941, Charles Huggins and a colleague showed that metastatic prostate cancer 
responds to endocrine manipulation,1 and this advance led to a Nobel Prize in 
Physiology or Medicine for Huggins in 1966. The endocrine responsiveness of 
prostate cancer continues to influence care today, with androgen-deprivation 
therapy remaining the standard of care for patients presenting with metastatic 
disease. Dr. Andrew Schally (who won the Nobel Prize in Physiology or Medicine 
in 1977) and colleagues elucidated the hypothalamic control of pituitary function.2 
The characterization of gonadotropin-releasing hormone analogues paved the way 
for medical therapy as an alternative to surgical therapy, and this approach is now 
the most commonly used method of androgen-deprivation therapy in developed 
countries. Surgical castration remains an effective, inexpensive alternative with 
some advantages.3
For men with an initial diagnosis of metastatic prostate cancer, continuous 
androgen-deprivation therapy represented the standard of care from 1941 until 
2015, when two trials (Androgen Ablation Therapy with or without Chemotherapy 
in Treating Patients with Metastatic Prostate Cancer [CHAARTED], ClinicalTrials.gov 
number, NCT00309985; and Systemic Therapy in Advancing or Metastatic Prostate 
Cancer: Evaluation of Drug Efficacy [STAMPEDE], NCT00268476) showed that 
androgen-deprivation therapy combined with six courses of docetaxel improved 
survival4,5 (Table 1). Docetaxel is a taxane that binds tubulin and stabilizes micro-
tubules, thereby inhibiting mitosis and androgen-receptor signaling by disrupting 
nuclear transport of the receptor.17 A meta-analysis of all available data from ran-
domized trials comparing docetaxel with the standard of care showed an overall 
survival benefit with docetaxel (hazard ratio for death, 0.77; 95% confidence in-
terval [CI], 0.68 to 0.87; P<0.001).18
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The CHAARTED study analyzed treatment 
with docetaxel in a subset of patients who had 
low-volume disease and a subset with high-volume 
disease (high-volume disease was defined as dis-
ease involving any visceral metastases or at least 
four bone lesions [with at least one lesion be-
yond the vertebral bodies and pelvis]).4 Whereas 
a considerable benefit was noted for patients with 
high-volume disease (hazard ratio for death, 0.61; 
95% CI, 0.45 to 0.81; P<0.001; median overall 
survival, 49.2 vs. 32.2 months), patients with 
low-volume disease had fewer events, with sur-
vival data not reaching statistical significance 
(hazard ratio for death, 0.60; 95% CI, 0.32 to 
1.13; P = 0.11); longer follow-up data are awaited. 
The distinction between high- and low-volume 
metastatic disease is incompletely explored be-
yond the CHAARTED study. Thus, in assessing 
data from other trials, distinctions between these 
subsets are unclear. Toxic effects of docetaxel 
included grade 3 or 4 febrile neutropenia (in 8 to 
12% of patients), neuropathies, alopecia, diarrhea, 
and fatigue.
The combination of androgen-deprivation ther-
apy and abiraterone with prednisone represents 
a new standard of care for metastatic disease 
that is based on data from the CHAARTED and 
STAMPEDE trials. Abiraterone inhibits andro-
genic steroid synthesis, targeting cytochrome 
P450 17A1 (CYP17A1) and blocking 17 alpha-
hydroxylase and 17,20 lyase.19 Recent studies in-
dicate that a common abiraterone metabolite is 
also an androgen-receptor antagonist, though 
its clinical significance has not yet been proved.20 
Abiraterone decreases androgens beyond the 
castrate state by inhibiting adrenal (and possibly 
intratumoral) steroid synthesis but increases 
steroid precursors upstream of CYP17, if given 
without glucocorticoids.21 Upstream accumula-
tion of steroid precursors can result in hypoka-
lemia and hypertension, as in hereditary CYP17 
deficiency.22 Abiraterone alone has antitumor ac-
tivity and has been safely administered without 
glucocorticoids, in combination with the mineralo-
corticoid receptor antagonist eplerenone, but full 
clinical activity is unproven.23 Administration of 
glucocorticoids in addition to abiraterone de-
creases upstream mineralocorticoids, as well as 
related adverse events, and may enhance anti-
cancer activity.24
The STAMPEDE trial and the LATITUDE trial 
(NCT01715285) evaluated androgen-deprivation 
therapy with or without abiraterone and a gluco-
corticoid (Table 1). The STAMPEDE trial ran-
domly assigned a total of 1917 patients to a 
study treatment, 1002 (52%) of whom had re-
ceived an initial diagnosis of metastatic disease.7 
For patients with metastatic disease, no land-
mark survival data were reported, but the reduc-
tion in the risk of death was substantial for 
those in the group that received abiraterone and 
prednisolone (hazard ratio, 0.61; 95% CI, 0.49 to 
0.75; P<0.001). For the STAMPEDE group as a 
whole, including both patients with metastatic 
disease and those with nonmetastatic disease, 
the 3-year survival rate was 76% for those who 
received androgen-deprivation therapy alone, as 
compared with 83% for those treated with abi-
raterone and prednisolone in addition to andro-
gen deprivation (hazard ratio with combination 
treatment, 0.63; 95% CI, 0.52 to 0.76; P<0.001).7 
There was heterogeneity in the outcome accord-
ing to age, with no survival benefit observed for 
combined treatment in men with metastatic or 
nonmetastatic disease who were more than 70 
years old.
The LATITUDE trial randomly assigned 1199 
men with metastatic prostate cancer to receive 
androgen-deprivation therapy with or without 
abiraterone and prednisone.6 Survival was clearly 
improved in the abiraterone group (hazard ratio 
for death, 0.62; 95% CI, 0.51 to 0.76; P<0.001). 
The 3-year survival rate was 66% for combina-
tion therapy, as compared with 49% for andro-
gen deprivation alone. Primary toxic effects in-
cluded hypertension, hypokalemia, and increased 
risk of elevated hepatic-enzyme levels.
Overall, these data provide the basis for add-
ing androgen-deprivation therapy combined with 
abiraterone and a glucocorticoid to the standard 
of care for patients with metastatic disease at 
diagnosis; however, neither trial prospectively 
planned crossover to abiraterone for patients 
with castration-resistant disease. Thus, the ques-
tion regarding earlier versus later treatment re-
mains unanswered. Earlier treatment raises con-
cerns about the increased risk of chronic toxic 
effects of glucocorticoids and androgen-depriva-
tion therapy — specifically, weight gain and my-
opathy with prednisone, and osteoporosis and 
metabolic and cardiovascular side effects with 
protracted, more intensive androgen deprivation.
Though the effectiveness of abiraterone and 
that of docetaxel in prolonging survival appear 
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to be equivalent,25 clear distinctions are noted in 
the duration of therapy used in previous trials 
for patients with an initial diagnosis of meta-
static disease. The docetaxel regimen is com-
pleted after 18 weeks (one infusion given every 
3 weeks, for a total of six infusions), whereas the 
abiraterone–prednisone regimen is given until 
disease progression, which may result in pro-
longed drug exposure. The duration and cost of 
treatment may influence clinical decision mak-
ing. Comparisons of docetaxel and abiraterone 
according to the duration of therapy have been 
incompletely explored.
Data from studies determining whether con-
temporaneous administration of androgen-depri-
vation therapy, docetaxel, and abiraterone–predni-
sone is superior to serial administration of these 
agents are awaited. Selection of patients for 
treatment on the basis of molecular biomarkers 
has been notably absent in studies of hormone 
treatment for patients with an initial diagnosis 
of metastatic disease.
As more therapies are proved to be effective 
for metastatic disease, the question of their effec-
tiveness in patients with nonmetastatic but high-
risk disease will arise. Such questions can be 
answered only by means of direct clinical trials.
De tec tion of Me ta s tatic Dise a se 
a nd Improv ed Im aging
The definition of metastatic disease depends on 
the type of imaging used. Older definitions were 
typically based on the use of radionuclide bone 
scanning and computed tomography (CT), but 
approaches to imaging are currently in a state of 
flux, with newer, more sensitive imaging meth-
ods detecting evidence of disease spread, even 
though conventional imaging shows no signs of 
metastasis. The implications of using more sen-
sitive imaging techniques, and their relationship 
to therapy, are not yet fully understood.
Improved imaging, including positron-emis-
sion tomography (PET) with prostate-specific 
membrane antigen (PSMA) or with choline or 
fluciclovine and whole-body magnetic resonance 
imaging (MRI), is enabling earlier and better 
identification of metastases.26,27 PSMA PET shows 
the expression of PSMA on the cell surface in 
prostate cancer. More accurate imaging may 
change the diagnosis from nonmetastatic to 
metastatic disease. However, pathological con-
firmation of positive imaging studies is incom-
plete. Earlier detection of metastases may affect 
treatment selection for both local and meta-
static disease. Trials evaluating treatment of 
oligometastatic disease with stereotactic body 
irradiation are under way. The usefulness of new 
imaging techniques in patients with prostate 
cancer will remain uncertain until a clinical 
benefit has been shown in trials that directly 
assess these techniques.
Tr e atmen t of the Pr im a r y Si te 
in Men w i th Me ta s tatic Dise a se
Because of better treatments for metastatic dis-
ease, men are living longer with local disease 
that may provide a sanctuary from systemic 
therapy and may result in an increased risk of 
local complications and a need for urologic inter-
ventions. Grade A evidence is needed to guide 
local treatment in men with metastatic disease. 
Trials addressing this issue are under way.
Pathoph ysiol o gic a l a nd Gene tic 
Fe at ur es of C a s tr ation-
R esis ta n t Pros tate C a ncer
Defects in Androgen-Receptor Signaling
Androgen-receptor signaling is altered in castra-
tion-resistant prostate cancer, with increased intra-
tumoral steroidogenesis, altered steroid-trans-
porter expression, increased androgen-receptor 
expression frequently due to gene copy-number 
gains, androgen-receptor gene mutations impart-
ing ligand promiscuity and activated by glucocor-
ticoids or androgen-receptor antagonist therapeu-
tics, and androgen-receptor gene rearrangements 
resulting in preferential expression of constitu-
tively active receptor splice variants.28-30 These 
androgen-receptor splice variants, the most com-
mon of which is AR-V7, can also be generated in 
the absence of gene rearrangements and can 
delete the androgen-receptor ligand-binding reg-
ulatory domain.31 Constitutive receptor-mediated 
transcriptional activation can occur despite the 
absence of ligand.32 Strategies targeting these 
splice variants are now being prioritized.
Somatic Genomic Alterations
Genomic aberrations in metastatic, castration-
resistant prostate cancer may be similar to or 
distinct from genomic alterations in primary 
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prostate tumors that have not been treated with 
androgen deprivation33,34 (Table 2). The most 
common alterations in patients with metastatic 
disease involve the androgen receptor (in >60% 
of patients), but p53 mutations or deletions are 
also common and can be concurrent with RB1 
loss, together leading to lineage plasticity from 
luminal to basal phenotypes.35 The loss of tumor 
suppressor PTEN, as well as other aberrations 
activating AKT signaling, and ETS rearrange-
ments (e.g., TMPRSS2–ERG) commonly occur to-
gether.34 SPOP mutations, which are found in 
10% of metastatic, castration-resistant prostate 
cancers, activate both androgen-receptor and 
AKT signaling.36 Deleterious DNA-repair aber-
rations in genes, including BRCA2, ATM, BRCA1, 
PALB2, and RAD51D, occur in 20 to 25% of pa-
tients.34 Defective mismatch repair has also been 
reported,34,37 and this may be missed by targeted 
exome or exon sequencing.37
The use of advanced genomic analysis is now 
feasible to a greater extent than ever before. 
Whether its use improves treatment decisions is 
not yet clear.
Germline Mutations
Deleterious germline DNA-repair defects (Table 3) 
are present in at least 12% of patients with 
metastatic, castration-resistant prostate cancer; 
the most common defects are alterations in 
BRCA2, CHEK2, and ATM.38 Germline DNA-repair 
mutations have implications not only for the 
patient’s treatment and prognosis but also for 
the care of family members.39,40 BRCA1/2 muta-
tions are highly penetrant for female family 
members, increasing the risk of breast or ovarian 
cancer. For male family members, penetrance is 
lower, but prostate cancer, breast cancer, and 
pancreatic cancer all occur at increased rates 
among those with BRCA mutations. Estimates of 
the incidence of prostate cancer by the age of 
80 years range from 19 to 61% for BRCA2 muta-
tions (depending on the risk scores for each mu-
tation) and from 7 to 26% for BRCA1 mutations.8
Germline mutations in mismatch-repair 
genes (MLH1, MSH2, MSH6, and PMS2) are clearly 
described in the Lynch syndrome and are also 
clearly described in a small percentage of men 
with advanced prostate cancer (0.6%), but con-
vincing evidence that these mutations contribute 
to an increased incidence of advanced disease 
is sparse. No increased mutational frequency in 
mismatch-repair genes has been detected among 
men with metastatic disease as compared with 
controls (men without prostate cancer).38
Tr e atmen t of C a s tr ation-
R esis ta n t Pros tate C a ncer
The first agent that was shown to prolong sur-
vival among men with metastatic, castration-resis-
Gene
% of Patients 
with Aberrant 
Gene Pathway
Common  
Aberrations†
AR gene 62.7 Androgen signaling Amplification, splice  
variants, mutation
TP53 53.3 Cell cycle or tumor  
suppressor
Mutation, copy loss
PTEN 40.7 PI3K–AKT regulator Copy loss, mutation
ETS 56.7 Transcriptional regulator Gene fusions
BRCA2 13.3 DNA repair Copy loss, mutation
KMT2C 12.7 Chromatin modifier Mutation
FOXA1 12.0 AR-associated Mutation
ZBTB16 10.0 AR-associated Copy loss
RB1 9.3 Cell cycle Copy loss
APC 8.7 Wnt pathway Copy loss, mutation
CHD1 8.0 Chromatin modifier Copy loss, mutation
SPOP 8.0 Androgen signaling Mutation
ATM 7.3 DNA repair Copy loss, mutation
*  Data are from Robinson et al.34 AR denotes androgen receptor.
†  Aberrations are listed in descending order of predominance (e.g., for TP53, 
mutation is the predominant gene alteration, and for PTEN, copy loss is pre-
dominant).
Table 2. Selected Gene Aberrations in Patients with Metastatic Prostate Cancer.*
Gene
% of Patients 
with Mutation
Relative Risk  
of Metastases†
BRCA2 5.35 18.6
CHEK2 1.87 3.1
ATM 1.59 6.3
BRCA1 0.87 3.9
GEN1 0.46 5.8
RAD51D 0.43 5.7
PALB2 0.43 3.5
*  Data are from Pritchard et al.37
†  Relative risks are for the comparison with men who do not 
have known prostate cancer.
Table 3. Selected Common Germline DNA-Repair 
Mutations in Patients with Metastatic Prostate Cancer.*
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tant prostate cancer was docetaxel. Two phase 3 
trials showed a significant overall survival benefit 
in 2004.9,15 One trial (TAX 327), which compared 
two schedules of docetaxel and prednisone with 
mitoxantrone and prednisone (control), showed 
improved overall survival for patients treated with 
75 mg of docetaxel per square meter of body-
surface area every 3 weeks (hazard ratio for death, 
0.76; 95% CI, 0.62 to 0.94; P = 0.009); the median 
survival was 18.9 months for this group and 
16.5 months for the control group.9 The second 
phase 3 trial (Southwest Oncology Group [SWOG] 
Intergroup protocol 99-16 [NCT00004001]), which 
compared docetaxel and estramustine, adminis-
tered in 3-week cycles, with mitoxantrone and 
prednisone, also showed superior overall sur-
vival with docetaxel.15 Given the toxic effects of 
estramustine, docetaxel at a dose of 75 mg per 
square meter with oral prednisone at a dose of 
5 mg twice a day became the de facto standard 
frontline chemotherapy regimen. Docetaxel has 
a variety of toxic effects, including bone marrow 
suppression, dysgeusia, alopecia, nail changes, 
and allergic reactions.
Clinical progress in treating metastatic, cas-
tration-resistant prostate cancer during the 
past 7 years has been remarkable. Pivotal trials 
resulting in an overall survival benefit have led 
to regulatory approval for two hormonal thera-
pies, an additional taxane, a bone-targeted and 
alpha-emitting radionuclide, and an immuno-
therapy.
In 2010, an autologous cellular immunothera-
peutic agent (sipuleucel-T) was shown to provide 
an overall survival benefit in the Immunotherapy 
for Prostate Adenocarcinoma Treatment (IMPACT) 
study (NCT00065442), a pivotal phase 3 trial com-
paring sipuleucel-T (administered every 2 weeks 
for a total of three doses) with an unstimulated 
cellular product in 512 patients with metastatic, 
castration-resistant prostate cancer who had min-
imal or no symptoms.13 For sipuleucel-T, autolo-
gous peripheral-blood mononuclear cells (includ-
ing antigen-presenting cells) were activated ex 
vivo with the use of a combination of cytokines 
and a recombinant fusion protein consisting of 
prostatic acid phosphatase and granulocyte–
macrophage colony-stimulating factor. The me-
dian overall survival was 25.8 months for patients 
receiving sipuleucel-T and 21.7 months for con-
trols (hazard ratio for death in the sipuleucel-T 
group, 0.78; 95% CI, 0.61 to 0.98; P = 0.03). Ad-
verse events included pyrexia, chills, fatigue, 
nausea, and headache.
Two new hormonal agents, abiraterone and 
enzalutamide, have had the largest effect on 
castration-resistant prostate cancer. The activity 
of 1000 mg of abiraterone and prednisone at a 
dose of 5 mg twice a day, as compared with 
placebo plus prednisone, was initially proved in 
a study involving patients with metastatic, castra-
tion-resistant prostate cancer who had been treat-
ed with docetaxel.10 An overall survival advantage 
with abiraterone and prednisone as compared 
with placebo and prednisone was noted (hazard 
ratio for death, 0.65; 95% CI, 0.54 to 0.77; 
P<0.001), with elevated liver-function values as 
mineralocorticoid-associated side effects (hyper-
tension, hypokalemia, and edema). The median 
overall survival was 14.8 months for the group 
treated with abiraterone and prednisone versus 
10.9 months for the control group.
The combination of abiraterone and pred-
nisone was subsequently compared with pla-
cebo and prednisone in the COU-AA-302 trial 
(NCT00887198) for the treatment of men with 
metastatic, castration-resistant disease, minimal 
or no symptoms and no previous chemotherapy.41 
Survival with no radiographic evidence of dis-
ease progression and overall survival were used 
as the coprimary end points. The initial analysis 
showed that the abiraterone–prednisone group 
had significantly improved progression-free sur-
vival (hazard ratio for radiographic evidence of 
progression, 0.53; 95% CI, 0.45 to 0.62; P<0.001), 
with a trend toward improved overall survival.41 
The final planned analysis showed a benefit of 
abiraterone and prednisone with respect to over-
all survival, with a median overall survival of 
34.7 months, versus 30.3 months with placebo 
and prednisone (hazard ratio for death, 0.81; 
95% CI, 0.70 to 0.93; P = 0.003).42 Mineralocorti-
coid-associated adverse events were noted, as well 
as occasional liver-function abnormalities and 
hyperglycemia.
Enzalutamide is a potent and new androgen-
receptor antagonist.14 The initial phase 3 trial 
(AFFIRM [A Study Evaluating the Efficacy and 
Safety of the Investigational Drug MDV3100], 
NCT00974311) evaluated enzalutamide for meta-
static, castration-resistant prostate cancer previ-
ously treated with docetaxel. Treatment with oral 
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enzalutamide at a dose of 160 mg per day was 
associated with improved overall survival, as com-
pared with placebo (hazard ratio for death, 0.63; 
95% CI, 0.53 to 0.75; P<0.001; median survival, 
18.4 months with enzalutamide vs. 13.6 months 
with placebo).43 Toxic effects included fatigue 
and hot flashes; seizures were reported in a small 
proportion of patients (<1%).
Enzalutamide at a dose of 160 mg per day 
also improved both radiographic progression-
free survival and overall survival in men with 
asymptomatic or mildly symptomatic disease 
who had not previously received chemotherapy 
(PREVAIL, NCT01212991).11 The hazard ratio for 
death with enzalutamide as compared with pla-
cebo was 0.71 (95% CI, 0.60 to 0.84; P<0.001). 
On the basis of the initial analysis, the median 
overall survival was 32.4 months with enzalu-
tamide and 30.2 months with placebo.43 The final 
analysis showed median estimates of 35.3 and 
31.3 months, respectively (hazard ratio for death 
with enzalutamide, 0.77; 95% CI, 0.67 to 0.88; 
P< 0.001).12 Adverse events in this trial did not 
include seizures but did include fatigue, falls, 
and nonpathologic fractures.
Cabazitaxel is a taxane specifically designed 
for antitumor activity in docetaxel-resistant 
models.44 The pivotal phase 3 trial (TROPIC, 
NCT00417079) evaluated cabazitaxel in patients 
with disease progression after treatment with 
docetaxel. Cabazitaxel at a dose of 25 mg per 
square meter was administered intravenously 
every 3 weeks. The end point was overall sur-
vival, with a median of 12.7 months in the con-
trol group and 15.1 months in the cabazitaxel 
group (hazard ratio for death with cabazitaxel, 
0.70; 95% CI, 0.59 to 0.83; P<0.001). Febrile neu-
tropenia and diarrhea were significantly more 
frequent in the cabazitaxel group than in the con-
trol group. In a subsequent phase 3 trial with a 
noninferiority design (PROSELICA, NCT01308580), 
a dose of 20 mg of cabazitaxel per square meter 
was noninferior to a dose of 25 mg per square 
meter with respect to overall survival, with the 
lower dose capturing at least 50% of the survival 
benefit of the higher dose with decreased toxic-
ity, making a dose of 20 mg per square meter an 
alternative standard of care.45
Radium-223 is an alpha-particle–emitting ra-
dionuclide that binds preferentially to the hy-
droxyapatite in osteoblastic bone metastases.16 A 
phase 3 trial (Alpharadin in Symptomatic Pros-
tate Cancer Patients [ALSYMPCA], NCT00699751) 
showed that radium-223 combined with the “best 
standard of care” resulted in improved overall 
survival, as compared with the best standard of 
care alone, for men who had symptomatic bone 
metastases without visceral metastasis and with-
out nodal metastases larger than 3 cm in the 
short-axis diameter.46 The best standard of care 
included older hormonal therapies (e.g., antiandro-
gens, glucocorticoids, and estrogens), bisphos-
phonates, and external-beam radiation therapy 
but excluded chemotherapies. Overall survival 
was prolonged in the radium-223 group (median, 
14.9 months, vs. 11.3 months in the control 
group; hazard ratio for death, 0.70; 95% CI, 0.58 
to 0.83; P<0.001). Patients who had not previ-
ously received chemotherapy and those previously 
treated with docetaxel both had improved over-
all survival with radium-223 as compared with 
placebo. Adverse events with radium-223 in-
cluded diarrhea and a small number of cases of 
thrombocytopenia.
Bone-targeted agents such as zoledronic acid 
and denosumab are approved by the Food and 
Drug Administration (FDA) for use in patients 
with castration-resistant prostate cancer and 
bone metastases in order to prevent skeletal 
adverse events such as pathologic fractures, 
spinal cord compression, and the effects of ra-
diation and surgery on bone. However, the use 
of these agents is somewhat controversial be-
cause a clinical benefit has not been clearly 
shown in patients receiving concomitant newer 
anticancer agents such as abiraterone and enzalu-
tamide.
Me ta s ta sis-fr ee Surv i va l
Multiple ongoing trials are evaluating antiandro-
gens as compared with placebo in men with 
nonmetastatic, castration-resistant prostate can-
cer, with metastasis-free survival as an end point. 
The definition of nonmetastatic prostate cancer, 
however, depends on the sensitivity of the imag-
ing technique used and is likely to change with 
improved PET and MRI technologies. It is not yet 
clear whether prolongation of the time to radio-
graphic evidence of metastases is clinically use-
ful or provides an overall survival benefit in this 
patient population.
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Compa r isons,  Combinations,  
a nd Sequencing
Multiple trials have shown improvement in over-
all survival with the use of various agents, but 
only one large trial to date has compared two 
life-prolonging therapies. That trial (FIRSTANA, 
NCT01308567) failed to show that cabazitaxel 
was superior to docetaxel in men with meta-
static, castration-resistant prostate cancer who 
had not received previous chemotherapy.47 Over-
all, grade A data support the use of sipuleucel-T, 
enzalutamide, abiraterone–prednisone, docetaxel, 
and radium-223 in selected populations of men 
with metastatic, castration-resistant prostate can-
cer who have not received previous chemother-
apy. Grade A evidence also supports the use of 
enzalutamide, abiraterone–prednisone, cabazi-
taxel, and radium-223 in selected patients after 
treatment with docetaxel. Grade A data are lack-
ing for combinations of these therapies or for 
sequential use, apart from the use of radium-223 
after docetaxel, leaving clinicians with imperfect 
guidance on treatment selection for individual 
patients.
Despite limitations, some consistent observa-
tions have arisen. First, cross-resistance occurs 
between the new androgen-receptor–targeting 
agents. The rate of response to abiraterone ther-
apy after treatment with enzalutamide is less 
than 10%, whereas the response rate for enzalu-
tamide after abiraterone is 15 to 30%.48-50 The 
benefit from taxanes appears to be diminished 
after treatment with abiraterone or enzaluta-
mide, as compared with the benefit in patients 
who have not received such treatment, although 
taxanes remain active.51 No large, prospective, 
randomized trials of treatment with taxanes in 
men previously treated with abiraterone or enzalu-
tamide have been completed. Thus, guidance in 
making treatment decisions for such patients is 
limited.
Combination therapy is being explored clini-
cally on several fronts (Table 4). Both enzalu-
tamide and apalutamide with or without abi-
raterone are being evaluated in large, prospective 
trials. A trial involving patients with disease 
progression during treatment with enzalutamide 
with or without abiraterone failed to meet the 
primary end point.52 Abiraterone with or without 
radium-223 and enzalutamide with or without 
radium-223 are both being evaluated but without 
overall survival as the primary end point.
Neuroend o cr ine a nd Sm a ll -
Cell Va r i a n t s of Pros tate 
C a ncer
Prostate cancer is typically adenocarcinoma, al-
though small-cell and neuroendocrine variants 
are described in a minority of cases. The small-
cell variant is typically CD56-positive with RB1 
deletion, and the usual treatment for this vari-
ant, like that for any other small-cell tumor, is 
usually a platinum-based regimen. The neuroen-
docrine variants are now a focus of considerable 
research, although from a pathological perspec-
tive, there is no consensus on definitions of these 
variants. Some evidence indicates that neuroen-
docrine tumors are more likely to arise after ex-
treme androgen deprivation, such as that induced 
by exposure to abiraterone or enzalutamide. 
Trials evaluating treatments for neuroendocrine 
tumors (variously defined) are under way but 
without practice-changing results to date.
Pro gnos tic a nd Pr edic ti v e 
Biom a r k er s
A variety of prognostic schemata have been pro-
posed, including many nomograms. Performance 
status; extent of disease; pain status; location of 
disease (e.g., bone or liver); levels of hemoglo-
bin, serum alkaline phosphatase, lactate dehy-
drogenase, albumin, aspartate aminotransfer-
ase, circulating tumor cells, and plasma cell-free 
DNA; neutrophil-to-lymphocyte ratio; and kinet-
ics of disease progression contribute to the 
prognosis.53-55
Predictive biomarkers are being explored. 
Androgen-receptor aberrations have been linked 
to resistance in various patient populations. 
AR-V7–encoding RNA expression in circulating 
tumor cells is associated with a poor prognosis 
and resistance to abiraterone and enzalutamide 
but not to taxanes.56,57 AR-V7 protein in tumor 
cells is also correlated with resistance to abi-
raterone and enzalutamide but not to taxanes.58 
Studies using circulating cell-free DNA assays 
have shown that androgen-receptor amplifica-
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Trial Treatment Regimen Comments
Trial  
Registration No.
Metastatic disease, no  
previous ADT
STAMPEDE, group H Standard of care with or without prostate  
irradiation
Enrollment complete NCT00268476
STAMPEDE, group J Standard of care with or without enzalutamide,  
abiraterone, and prednisolone
Enrollment complete NCT00268476
ENZAMET ADT plus antiandrogen vs. ADT plus enzalutamide Enrollment complete NCT02446405
STAMPEDE, group K Standard of care with or without metformin Enrollment ongoing NCT00268476
STAMPEDE, group L Standard of care with or without transdermal  
estrogen
Enrollment ongoing NCT00268476
PEACE-1 ADT with or without docetaxel, with or without 
prostate irradiation, with or without abiraterone 
and prednisone
Enrollment ongoing NCT01957436
ARASENS ADT plus docetaxel with or without darolutamide Enrollment ongoing NCT02799602
SWOG 1216 ADT plus bicalutamide vs. ADT plus orteronel Enrollment ongoing NCT01809691
Metastatic CRPC
VIABLE Docetaxel with or without DCVAC Enrollment ongoing NCT02111577
Alliance A031201 Enzalutamide with or without abiraterone and 
prednisone
Enrollment complete NCT01949337
IPATential150 Abiraterone and prednisone, with or without  
ipatasertib
Enrollment ongoing: biomarker-
stratified PTEN loss
NCT03072238
IMbassador250 Enzalutamide with or without atezolizumab Enrollment ongoing (after  
abiraterone or enzalutamide)
NCT03016312
CRPC with bone metastasis
PEACE-3 Enzalutamide with or without radium-223 Enrollment ongoing NCT02194842
ERA 223† Abiraterone with or without radium-223 Enrollment complete NCT02043678
Metastatic CRPC with DNA-
repair mutation, PARP-
inhibitor studies
TRITON3 Physician’s choice vs. rucaparib No prior treatments for CRPC 
required
NCT02975934
PROfound Enzalutamide or abiraterone vs. olaparib Administered after abiraterone 
or enzalutamide
NCT02987543
Galahad Niraparib (phase 2) Administered after abiraterone 
or enzalutamide and after 
docetaxel
NCT02854436
Nonmetastatic CRPC
SPARTAN‡ Placebo vs. apalutamide Enrollment complete NCT01946204
ARAMIS Placebo vs. darolutamide Enrollment ongoing NCT02200614
PROSPER‡ Placebo vs. enzalutamide Enrollment ongoing NCT02003924
*  According to the STAMPEDE trial results in 2015, the standard of care is androgen-deprivation therapy plus optional docetaxel if the clinician 
recommends it. CRPC denotes castration-resistant prostate cancer.
†  The ERA 223 trial was unblinded in December 2017 after a recommendation from an independent data monitoring committee regarding 
safety concerns focused on bone fractures and survival.
‡  Data from the SPARTAN and PROSPER trials will be presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium 
in February 2018.
Table 4. Selected Potentially Practice-Changing Trials in Progress.*
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tion and certain mutations (positions 702 and 
878) are also associated with resistance to abi-
raterone and enzalutamide.29,59,60 The clinical use-
fulness of these assays has yet to be ascertained 
in large, prospective studies, and the assay re-
sults may not be assessable in all patients.
Deleterious somatic and germline aberrations 
in DNA-repair genes are common in men with 
metastatic, castration-resistant prostate cancer.34 
Homologous recombination repair defects, the 
most common of which is BRCA2, may confer 
sensitivity to poly(adenosine diphosphate [ADP]–
ribose) polymerase (PARP) inhibitors and platinum-
based therapy.61,62 Multiple trials of PARP inhibi-
tors in this patient population are ongoing.
Mismatch repair in tumor cells is deficient in 
5 to 12% of men with metastatic, castration-
resistant prostate cancer.34,37,38 Pembrolizumab, 
an antibody that targets programmed death 1 
(PD-1), is now approved by the FDA for cancers 
with defective mismatch repair.63 Further studies 
are needed to elucidate the relationship between 
this disease state and immunotherapy. Prelimi-
nary data indicate that not all men with tumors 
that are deficient in mismatch repair have a re-
sponse to immunotherapy, although impressive 
responses have been reported in some cases. 
Response rates in the range of 10 to 20% have 
been reported for molecularly unselected men 
treated with PD-1 inhibition.64,65
Loss of PTEN expression, which is common 
in metastatic, castration-resistant prostate cancer 
(observed in >40% of cases), activates AKT sig-
naling.34,66,67 Targeting the AKT kinase may have 
therapeutic value in men with PTEN loss.68 Stud-
ies of inhibitors of this pathway are ongoing.
PSMA is expressed in most tumors, although 
intrapatient heterogeneity of expression has been 
reported.69 PSMA ligands or anti-PSMA antibod-
ies can be conjugated to radionuclides (either 
alpha- or beta-particle emitters) or cytotoxic 
agents, and multiple PSMA strategies are cur-
rently undergoing evaluation.70-73
R esponse a nd Sur ro g ate 
Biom a r k er s
The validation and clinical qualification of im-
proved response and surrogate biomarkers are 
a high priority in research on prostate cancer. 
Biomarkers, including circulating tumor-cell 
counts and cell-free DNA, have shown promise.74 
Radiographic evidence of progression-free sur-
vival, with the use of CT scans and bone scans, 
has been evaluated as a response biomarker,75 
but surrogacy for an overall survival benefit has 
not been shown. Clinical deterioration may be 
more important than radiographic progression,76 
but full acceptance of this end point has not 
been verified.
Unme t Needs,  Ch a llenges,  
a nd Opport uni ties
Advanced prostate cancer is a disease that reli-
ably progresses and is fatal. Today, the new 
hormonal agents are typically used for the treat-
ment of prostate cancer before chemotherapy, 
but large, prospective trials involving patients 
with disease progression while receiving treat-
ment with abiraterone or enzalutamide have 
failed to yield clear evidence that these new 
hormonal agents provide a clinical benefit. Opti-
mal sequencing of the various agents is cur-
rently unknown. Furthermore, despite a ratio-
nale for combination therapy (which is typically 
used for most cancers), no large, randomized 
trials testing combination therapy for advanced 
prostate cancer have been reported to date.
Though newer studies indicate that a variety 
of potentially actionable genetic alterations can 
be detected in prostate cancer, no therapy tar-
geting these alterations has yet been shown to 
have a clinical benefit. Novel forms of immuno-
therapy, especially PD-1 inhibitors, are active in 
a variety of cancers, especially those with high 
mutational frequencies. Prostate cancer has a 
lower mutational burden, and the use of PD-1 
inhibitors for prostate cancer remains experi-
mental (though the activity of these agents may 
be higher in tumors with defective mismatch 
repair than in tumors with other genetic altera-
tions). Thus, advanced genetics and immunol-
ogy, two major drivers of progress in oncology, 
are not routinely incorporated into the care of 
patients with prostate cancer.
Although we celebrate the life-prolonging ef-
fects of the new hormonal therapies, the diagno-
sis of metastatic prostate cancer currently leads 
to lifelong androgen-deprivation therapy. Despite 
progress on multiple research fronts, we have 
imperfect tools to identify patients who need 
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therapy in the first place, and once the disease 
spreads beyond the control of local therapies, we 
do not know how best to sequence or combine 
the expanding number of active therapies.
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